KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Common Equity (2016 - 2025)

Moderna (MRNA) has disclosed Common Equity for 10 consecutive years, with $8.6 billion as the latest value for Q4 2025.

  • Quarterly Common Equity fell 20.65% to $8.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.6 billion through Dec 2025, down 20.65% year-over-year, with the annual reading at $8.6 billion for FY2025, 20.65% down from the prior year.
  • Common Equity for Q4 2025 was $8.6 billion at Moderna, down from $9.3 billion in the prior quarter.
  • The five-year high for Common Equity was $19.1 billion in Q4 2022, with the low at $25.0 million in Q1 2025.
  • Average Common Equity over 5 years is $12.2 billion, with a median of $12.4 billion recorded in 2024.
  • The sharpest move saw Common Equity skyrocketed 452.32% in 2021, then plummeted 99.8% in 2025.
  • Over 5 years, Common Equity stood at $14.1 billion in 2021, then soared by 35.19% to $19.1 billion in 2022, then decreased by 27.55% to $13.9 billion in 2023, then dropped by 21.32% to $10.9 billion in 2024, then fell by 20.65% to $8.6 billion in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $8.6 billion, $9.3 billion, and $9.4 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.